Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Puma Biotechnology is a commercial-stage biopharmaceutical company focused on oncology, primarily generating revenue from NERLYNX (neratinib), an oral tyrosine kinase inhibitor approved for extended adjuvant treatment of HER2-positive breast cancer and metastatic HER2-positive breast cancer in combination with capecitabine. The company operates in a competitive oncology market dominated by larger players like Roche and Pfizer, with NERLYNX facing headwinds from newer HER2-targeted therapies and generic competition, resulting in declining revenue trends despite improved profitability through cost optimization.
Puma generates revenue primarily through commercial sales of NERLYNX, a differentiated oral HER2-targeted therapy with extended adjuvant indication approved by FDA in 2017. The company operates a lean commercial infrastructure focused on oncology specialists and breast cancer treatment centers. Pricing power is moderate given competitive pressure from Herceptin biosimilars, Kadcyla, and newer agents like Enhertu. Gross margins are strong at 72% reflecting pharmaceutical economics, but the company faces patent expiration risks (key patents expire 2026-2030s) and limited pipeline diversification. Profitability has improved significantly through operational restructuring and reduced R&D spend after discontinuing certain clinical programs.
NERLYNX quarterly prescription volume trends and market share in extended adjuvant HER2+ breast cancer setting
Clinical trial readouts for expanded indications or combination therapies that could extend product lifecycle
Competitive developments in HER2-targeted therapy landscape (new drug approvals, guideline changes, biosimilar pricing)
Strategic transaction speculation (acquisition interest, licensing deals, or asset sales given small market cap)
Cash burn rate and runway given $0.0B operating cash flow and potential need for capital
Patent cliff exposure with key NERLYNX composition-of-matter patents expiring between 2026-2030, creating generic competition risk within 4-8 years without pipeline replenishment
Evolving HER2+ breast cancer treatment paradigm with antibody-drug conjugates (Enhertu) demonstrating superior efficacy, potentially marginalizing oral TKI approaches
Regulatory and reimbursement pressure on specialty pharmaceutical pricing, particularly for products with established competition
Single-product dependency with no meaningful pipeline diversification creates binary commercial risk
Dominant competition from Roche (Herceptin, Perjeta, Kadcyla) and Daiichi/AstraZeneca (Enhertu) with superior clinical profiles and market access
Biosimilar erosion of HER2-targeted therapy market reducing overall pricing and market size for extended adjuvant setting
Clinical guideline evolution potentially narrowing NERLYNX's target patient population or positioning it as later-line therapy
Near-zero operating and free cash flow ($0.0B TTM) despite reported profitability raises questions about cash generation sustainability and working capital dynamics
Small market cap ($0.3B) limits financial flexibility and makes company vulnerable to capital markets volatility
Potential need for additional financing or strategic transaction if cash burn accelerates or revenue decline continues
low - Oncology pharmaceuticals are non-discretionary healthcare spending with minimal correlation to GDP or economic cycles. Breast cancer treatment decisions are driven by clinical need rather than economic conditions. However, severe recessions could impact insurance coverage dynamics and patient out-of-pocket costs affecting adherence.
Rising interest rates create modest headwinds through higher discount rates applied to future cash flows, particularly relevant for small-cap biotech with limited near-term profitability. The company's 0.36 debt-to-equity ratio suggests minimal direct financing cost impact. Higher rates also reduce appeal of speculative growth stocks, potentially pressuring valuation multiples for small biotech names. Access to capital markets for potential future financing becomes more expensive in high-rate environments.
Minimal direct credit exposure. The business model does not involve significant lending or credit-dependent customers. Indirect exposure exists through healthcare payer mix - government payers (Medicare/Medicaid) provide more stable reimbursement than commercial insurers during credit stress. Tightening credit conditions could impact hospital budgets and formulary access decisions, though oncology drugs typically maintain priority status.
value - The stock attracts deep-value investors and special situations funds given 135% one-year return, low valuation multiples (1.6x P/S, 6.5x EV/EBITDA), and potential as acquisition target. The combination of declining revenue, improving profitability, and small market cap creates classic value/turnaround profile. High ROE (36%) and ROA (23%) despite revenue headwinds suggests operational efficiency focus. Not suitable for growth investors given negative revenue trajectory and limited pipeline.
high - Small-cap biotech with single-product revenue concentration exhibits elevated volatility. The 33-135% returns across 3-12 month periods demonstrate significant price swings typical of sub-$500M market cap pharmaceutical companies. Stock is highly sensitive to clinical news, competitive developments, and M&A speculation. Limited institutional ownership and low trading liquidity amplify volatility during sector rotations.